Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

被引：0

作者：

R. Mercieca-Bebber

E. H. Barnes

K. Wilson

Z. Samoon

E. Walpole

T. Mai

S. Ackland

M. Burge

G. Dickie

D. Watson

J. Leung

T. Wang

R. Bohmer

D. Cameron

J. Simes

V. Gebski

M. Smithers

J. Thomas

J. Zalcberg

A. P. Barbour

机构：

[1] University of Sydney,National Health and Medical Research Council (NHMRC) Clinical Trials Centre, Faculty of Medicine and Health

[2] Princess Alexandra Hospital,Division of Cancer Services

[3] University of Queensland,School of Clinical Medicine

[4] The University of Queensland,Faculty of Medicine

[5] University of Newcastle,School of Medicine and Public Health

[6] Royal Brisbane and Women’s Hospital,Cancer Care Services

[7] Flinders University,Discipline of Surgery, College of Medicine and Public Health

[8] GenesisCare St Andrew’s Hospital,Crown Princess Mary Cancer Center, Westmead hospital; Faculty of Medicine and Health

[9] University of Sydney,School of Public Health and Preventive Medicine

[10] Hobart Private Hospital,undefined

[11] Townsville University Hospital,undefined

[12] Divisions of Surgery and Cancer Services,undefined

[13] Princess Alexandra Hospital,undefined

[14] GIAST Clinic Mater Medical Centre South Brisbane,undefined

[15] Monash University,undefined

来源：

BMC Cancer | / 22卷

关键词：

Oesophageal adenocarcinoma; Gastro-oesophageal adenocarcinoma; Neoadjuvant therapy; Quality of life; Patient-reported outcomes;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 Trial
Fuyuhiko Motoi
Kazuyuki Ishida
Fumiyoshi Fujishima
Shigeru Ottomo
Masaya Oikawa
Takaho Okada
Hiromune Shimamura
Shinichi Takemura
Fuminori Ono
Masanori Akada
Kei Nakagawa
Yu Katayose
Shinichi Egawa
Michiaki Unno
Annals of Surgical Oncology, 2013, 20 : 3794 - 3801
[32] Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 Trial
Motoi, Fuyuhiko
Ishida, Kazuyuki
Fujishima, Fumiyoshi
Ottomo, Shigeru
Oikawa, Masaya
Okada, Takaho
Shimamura, Hiromune
Takemura, Shinichi
Ono, Fuminori
Akada, Masanori
Nakagawa, Kei
Katayose, Yu
Egawa, Shinichi
Unno, Michiaki
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (12) : 3794 - 3801
[33] Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme
Yu, M.
Van Brunt, K.
Varnado, O. J.
Boye, K. S.
DIABETES OBESITY & METABOLISM, 2016, 18 (04): : 419 - 424
[34] An AGITG trial - A randomised phase II study of pre-operative cisplatin, fluorouracil and DOCetaxel plus /-radio Therapy based on poOR early response to cisplatin and fluorouracil for resectable esophageal adenocarcinoma
Barbour, A.
Walpole, E.
Mai, G. T.
Chan, H.
Barnes, E.
Watson, D.
Ackland, S.
Wills, V.
Martin, J.
Burge, M.
Karapetis, C.
Shannon, J.
Nott, L.
Gebski, V.
Wilson, K.
Thomas, J.
Lampe, G.
Zalcberg, J.
Simes, J.
Smithers, M.
ANNALS OF ONCOLOGY, 2016, 27
[35] CANAKINUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RECURRENT FEVER SYNDROMES: RESULTS FROM A PHASE 3 TRIAL (CLUSTER)
Lachmann, Helen J.
Lauwerys, Bernard
Miettunen, Paivi
Kallinich, Tilmann
Horneff, Gerd
Brik, Riva
Manna, Rafaelle
Murias, Sara
Savic, Sinisa
Smeets, Serge
De Benedetti, Fabrizio
Simon, Anna
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 207 - 208
[36] Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Bessette, Louis
Joven-Ibanez, Beatriz
Selmi, Carlo
Chen, Naijun
Kato, Koji
Lippe, Ralph
Zueger, Patrick
Patel, Jayeshkumar
Merola, Joseph
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 465 - 468
[37] Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: Patient-Reported Outcomes of a Randomized Phase II Trial
Bakkers, C.
Rovers, K. P.
Rijken, A.
Simkens, G. A. A. M.
Bonhof, C. S.
Nienhuijs, S. W.
Burger, J. W. A.
Creemers, G. J. M.
Brandt-Kerkhof, A. R. M.
Tuynman, J. B.
Aalbers, A. G. J.
Wiezer, M. J.
de Reuver, P. R.
van Grevenstein, W. M. U.
Hemmer, P. H. J.
Punt, C. J. A.
Tanis, P. J.
Mols, F.
de Hingh, I. H. J. T.
ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (05) : 2678 - 2688
[38] Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: Patient-Reported Outcomes of a Randomized Phase II Trial
C. Bakkers
K. P. Rovers
A. Rijken
G. A. A. M. Simkens
C. S. Bonhof
S. W. Nienhuijs
J. W. A. Burger
G. J. M. Creemers
A. R. M. Brandt-Kerkhof
J. B. Tuynman
A. G. J. Aalbers
M. J. Wiezer
P. R. de Reuver
W. M. U. van Grevenstein
P. H. J. Hemmer
C. J. A. Punt
P. J. Tanis
F. Mols
I. H. J. T. de Hingh
Annals of Surgical Oncology, 2023, 30 : 2678 - 2688
[39] Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: Results from the DURABLE trial
Lee, Lauren J.
Fahrbach, Jessie L.
Nelson, Lauren M.
McLeod, Lori D.
Martin, Sherry A.
Sun, Peter
Weinstock, Ruth S.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 89 (02) : 157 - 166
[40] Completion of Patient-Reported Outcome Measures Improved With Use of a Mobile Application in Arthroplasty Patients: Results From a Randomized Controlled Trial
Miller, Matthew D.
Redfern, Roberta E.
Anderson, Mike B.
Abshagen, Scott
Van Andel, David
Lonner, Jess H.
JOURNAL OF ARTHROPLASTY, 2024, 39 (07): : 1656 - 1662

← 1 2 3 4 5 →